Alliqua BioMedical, Inc. (NASDAQ:ALQA) received a $2.00 price target from equities researchers at HC Wainwright in a research report issued to clients and investors on Friday. The firm presently has a “buy” rating on the stock.
Separately, ValuEngine cut Alliqua BioMedical from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $1.31.
Shares of Alliqua BioMedical (NASDAQ:ALQA) opened at 0.2616 on Friday. The stock’s market capitalization is $12.03 million. The company has a 50 day moving average price of $0.36 and a 200-day moving average price of $0.45. Alliqua BioMedical has a 52-week low of $0.26 and a 52-week high of $1.13.
Alliqua BioMedical (NASDAQ:ALQA) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.05. Alliqua BioMedical had a negative return on equity of 75.87% and a negative net margin of 145.99%. The company had revenue of $5.52 million for the quarter, compared to analysts’ expectations of $5.01 million. During the same period in the previous year, the firm posted ($0.22) EPS. Alliqua BioMedical’s revenue was up 23.5% compared to the same quarter last year. On average, analysts predict that Alliqua BioMedical will post ($0.62) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “HC Wainwright Reiterates “$2.00” Price Target for Alliqua BioMedical, Inc. (NASDAQ:ALQA)” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/2801208/hc-wainwright-reiterates-2-00-price-target-for-alliqua-biomedical-inc-nasdaqalqa.html.
Several hedge funds and other institutional investors have recently modified their holdings of ALQA. Renaissance Technologies LLC boosted its position in shares of Alliqua BioMedical by 23.2% in the fourth quarter. Renaissance Technologies LLC now owns 410,400 shares of the company’s stock valued at $242,000 after buying an additional 77,400 shares in the last quarter. KCG Holdings Inc. boosted its position in shares of Alliqua BioMedical by 777.7% in the first quarter. KCG Holdings Inc. now owns 525,077 shares of the company’s stock valued at $265,000 after buying an additional 465,256 shares in the last quarter. Sabby Management LLC boosted its position in shares of Alliqua BioMedical by 93.7% in the first quarter. Sabby Management LLC now owns 2,131,050 shares of the company’s stock valued at $1,076,000 after buying an additional 1,030,652 shares in the last quarter. Finally, Perceptive Advisors LLC boosted its position in shares of Alliqua BioMedical by 120.3% in the first quarter. Perceptive Advisors LLC now owns 4,233,951 shares of the company’s stock valued at $2,136,000 after buying an additional 2,312,000 shares in the last quarter. Institutional investors and hedge funds own 24.02% of the company’s stock.
Alliqua BioMedical Company Profile
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
Receive News & Ratings for Alliqua BioMedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.